Statement by the board of directors of EQL Pharma AB by reason of Fårö Capital AB’s mandatory offer
NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. The board of directors[1] %202019-04-11.DOCX#_ftn1) (the “Board of Directors”) of EQL Pharma AB (“EQL Pharma” or